Portal de investigação
Impact of Mirikizumab Therapy on Histologic Measures of Intestinal Inflammation in a Phase 2 Study of Patients With Moderately- to Severely-Active Crohn's Disease
Unidades de investigação
Abstract
Abstract no disponible
Filiações
Filiações não disponíveis
Proyectos asociados
Gut microbiome and IBD therapy: an interplay?
Investigador Principal: Fernando José Magro Dias
Estudo Observacional Académico (GutIBD) . 2021
Iron deficiency and inflammatory bowel disease. Correlation with inflammation and Vitamin D status.
Investigador Principal: Fernando José Magro Dias
Estudo Observacional Académico (IronIBD) . 2021
Looking 4WARD: The role of dipeptidyl peptidase 4 (DPP-4) in inflammatory bowel disease (IBD) as a novel biomarker for predicting disease activity and monitoring response to therapy in IBD patients.
Investigador Principal: Fernando José Magro Dias
Estudo Observacional Académico (4WARD) . 2021
Isolated Ulceration of Crohn’s Anastomosis
Investigador Principal: Fernando José Magro Dias
Estudo Clínico Académico . 2021
Therapeutic Drug Monitoring: An Emergent Approach in Inflammatory Bowel Disease
Investigador Principal: Fernando José Magro Dias
Estudo Clínico Académico . 2021
Contributo da endoscopia, biomarcadores e imagiologia na evolução clinica dos doentes com doença inflamatória intestinal
Investigador Principal: Fernando José Magro Dias
Estudo Clínico Académico . 2019
Citar a publicação
Pai,R,De Hertogh,G,Reinisch,W,Harpaz,N,Feagan,BG,Agada,N,Pollack,P et al. Impact of Mirikizumab Therapy on Histologic Measures of Intestinal Inflammation in a Phase 2 Study of Patients With Moderately- to Severely-Active Crohn's Disease. Annual Scientific Meeting and Postgraduate Course of the American-College-of-Gastroenterology (ACG). 2021. TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA:Springer Nature. 2021 p.p. 421-422.
